<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  Label Free Nucleic Acid Assays for POC Diagnostics</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/01/2010</AwardEffectiveDate>
<AwardExpirationDate>04/30/2013</AwardExpirationDate>
<AwardTotalIntnAmount>499948.00</AwardTotalIntnAmount>
<AwardAmount>540594</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Ruth Shuman</SignBlockName>
<PO_EMAI>rshuman@nsf.gov</PO_EMAI>
<PO_PHON>7032922160</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase II project proposes to develop a for point-of-care (POC) nucleic acid assay for STD (sexually transmitted diseases) diagnostics using Electrochemical Impedance Spectroscopy (EIS).  Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) infections are two of the most common sexually transmitted diseases worldwide. The company proposes to develop a multiplex assay and testing platform for the direct detection of CT and GC rRNA using EIS-based assays and a sensor array.  In a final product for clinical settings, collected sample (e.g., swab or urine) will be processed on-cartridge, with all cartridges provided in a sealed, RNase-free package. &lt;br/&gt;&lt;br/&gt;The broader impact/commercial potential of this project will address the unmet market needs for a rapid and cost-effective nucleic acid based POC system to diagnose individuals with infectious disease-causing agents or toxins in nontraditional health care settings. Often persons who present to a clinic for STD testing never return to the clinic to receive their STD test result.  Thus, the availability of a POC test that can immediately provide results at the clinic is highly desirable.  Current POC tests lack sensitivity, which may lead to high false negative as well as false positive results. The company proposes to develop an inexpensive, highly sensitive, easy-to-use POC STD device to address this compelling market need.  In addition, the EIS-based biosensor system could be adapted for the POC detection of other infectious diseases.</AbstractNarration>
<MinAmdLetterDate>08/24/2010</MinAmdLetterDate>
<MaxAmdLetterDate>09/09/2012</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1026459</AwardID>
<Investigator>
<FirstName>Kumar</FirstName>
<LastName>Subramanian</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Kumar Subramanian</PI_FULL_NAME>
<EmailAddress>kumar@phoenixbiosystem.com</EmailAddress>
<PI_PHON>9259985075</PI_PHON>
<NSF_ID>000155847</NSF_ID>
<StartDate>08/24/2010</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Phoenix Biosystems</Name>
<CityName>Pleasanton</CityName>
<ZipCode>945668616</ZipCode>
<PhoneNumber>9258580484</PhoneNumber>
<StreetAddress>6833 Corte Munras</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<StateCode>CA</StateCode>
<CONGRESSDISTRICT>15</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CA15</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>032758695</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PHOENIX BIOSYSTEM, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Phoenix Biosystems]]></Name>
<CityName>Pleasanton</CityName>
<StateCode>CA</StateCode>
<ZipCode>945668616</ZipCode>
<StreetAddress><![CDATA[6833 Corte Munras]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>California</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>15</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CA15</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1591</Code>
<Text>STTR Phase II</Text>
</ProgramElement>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>1491</Code>
<Text>BIOTECH, BIOCHEM &amp; BIOMASS ENG</Text>
</ProgramReference>
<ProgramReference>
<Code>169E</Code>
<Text>SBIR Tech Enhan Partner (TECP)</Text>
</ProgramReference>
<ProgramReference>
<Code>5373</Code>
<Text>SMALL BUSINESS PHASE II</Text>
</ProgramReference>
<ProgramReference>
<Code>9107</Code>
<Text>BIOELECTRONICS AND BIONETWORKS</Text>
</ProgramReference>
<ProgramReference>
<Code>9183</Code>
<Text>GENERAL FOUNDATIONS OF BIOTECHNOLOGY</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
<Appropriation>
<Code>0110</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<Appropriation>
<Code>0112</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2010~450495</FUND_OBLG>
<FUND_OBLG>2012~90099</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves /> <w:TrackFormatting /> <w:PunctuationKerning /> <w:ValidateAgainstSchemas /> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF /> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables /> <w:SnapToGridInCell /> <w:WrapTextWithPunct /> <w:UseAsianBreakRules /> <w:DontGrowAutofit /> <w:SplitPgBreakAndParaMark /> <w:DontVertAlignCellWithSp /> <w:DontBreakConstrainedForcedTables /> <w:DontVertAlignInTxbx /> <w:Word11KerningPairs /> <w:CachedColBalance /> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math" /> <m:brkBin m:val="before" /> <m:brkBinSub m:val=" " /> <m:smallFrac m:val="off" /> <m:dispDef /> <m:lMargin m:val="0" /> <m:rMargin m:val="0" /> <m:defJc m:val="centerGroup" /> <m:wrapIndent m:val="1440" /> <m:intLim m:val="subSup" /> <m:naryLim m:val="undOvr" /> </m:mathPr></w:WordDocument> </xml><![endif]--></p> <p><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"   DefSemiHidden="true" DefQFormat="false" DefPriority="99"   LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Normal" /> <w:LsdException Locked="false" Priority="9" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="heading 1" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8" /> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9" /> <w:LsdException Locked="false" Priority="39" Name="toc 1" /> <w:LsdException Locked="false" Priority="39" Name="toc 2" /> <w:LsdException Locked="false" Priority="39" Name="toc 3" /> <w:LsdException Locked="false" Priority="39" Name="toc 4" /> <w:LsdException Locked="false" Priority="39" Name="toc 5" /> <w:LsdException Locked="false" Priority="39" Name="toc 6" /> <w:LsdException Locked="false" Priority="39" Name="toc 7" /> <w:LsdException Locked="false" Priority="39" Name="toc 8" /> <w:LsdException Locked="false" Priority="39" Name="toc 9" /> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption" /> <w:LsdException Locked="false" Priority="10" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Title" /> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font" /> <w:LsdException Locked="false" Priority="11" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Subtitle" /> <w:LsdException Locked="false" Priority="22" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Strong" /> <w:LsdException Locked="false" Priority="20" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="Emphasis" /> <w:LsdException Locked="false" Priority="59" SemiHidden="false"    UnhideWhenUsed="false" Name="Table Grid" /> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text" /> <w:LsdException Locked="false" Priority="1" SemiHidden="false"    UnhideWhenUsed="false" QFormat="true" Name="No Spacing" /> <w:LsdException Locked="false" Priority="60" SemiHidden="false"    UnhideWhenUsed="false" Name="Light Shading" /> <w:...]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[   Normal 0     false false false  EN-US X-NONE X-NONE              MicrosoftInternetExplorer4                                                                                                                                                               Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) infections are two of the most common sexually transmitted infections worldwide. In the United States alone, an estimated      1 Million new cases of CT and over 350,000 new cases of GC infections were reported in 2008. They also cost a lot of money. The U.S. spends an estimated $15.9 billion annually on direct medical care for STDs. Also critical are the intangible costs, including the psychological and emotional injury caused by infertility and ectopic pregnancy. These infections are particularly hazardous to women since many, if not most infections are asymptomatic and, if left untreated, these infections may lead to severe complications. CT can cause nongonococcal urethritis, epididymitis, proctitis, cervicitis, acute salpingitis, and Pelvic Inflammatory Disease (PID). Compared to older adults, sexually-active adolescents 13 to 19 years of age and young adults 20 to 24 years of age are at higher risk for acquiring STDs for a combination of behavioral, biological, and cultural reasons.  Up to half of patients diagnosed may be infected with both CT &amp; GC pathogens and, therefore, it is important to test all sexually active individuals for both CT and GC. Infections with GC are significant because optimal antibacterial therapy differs for the treatment of this infection and for CT. Gonorrhea has also been shown to facilitate the transmission of HIV.    Previous studies on STD clinic populations have shown that up to 20% of patients with positive chlamydia or gonorrhea tests fail to return for treatment within 30 days, and an additional 30% fail to return two weeks after test results. These people are likely to remain infectious and contribute substantially to the spread of these diseases in the community.  As many as 30% of untreated or uncured CT infections progress to PID, and each case of PID averages over $4,000 in future medical costs.  Therefore, the need for patient side testing to assure prompt treatment for chlamydial and gonococcal infections is evident.  Rapid testing is a promising approach to addressing this problem.  By enabling diagnosis and treatment in a single visit, the number of CT patients lost-to-follow-up and thus going untreated is reduced. The ability to obtain easily available Point-Of-Care (POC) tests in primary care clinics and inner city clinics may have a far reaching impact on the rates of STIs in this country.  From modeling and cost-benefit analyses the bottom line for rapid diagnostic tests is clear &ndash; when we have them, we should use them.    This SBIR Phase II encompasses late stage development of our multiplexed label-free POC platform. CT/GC POC monitoring is the first application of our technology. We have demonstrated a fully functional, field deployable device that detects and quantifies CT and GC from clinical samples. The completion of Phase II has resulted in an optimized general use POC technology platform that could be further developed for infectious disease diagnostics among other compelling clinical applications.           Last Modified: 07/09/2013       Submitted by: Kumar Subramanian]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
